Orbifloxacin
Chemical compound
- QJ01MA95 (WHO)
- Veterinary use only
- 1-Cyclopropyl-7-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- 113617-63-3 N
- 60605
- 54631 Y
- 660932TPY6
- D08299 Y
- ChEMBL295433 Y
- DTXSID7046201
- Interactive image
- O=C(O)C1=CN(C2CC2)c3c(C1=O)c(F)c(F)c(c3F)N4C[C@H](C)N[C@H](C)C4
InChI
- InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+ Y
- Key:QIPQASLPWJVQMH-DTORHVGOSA-N Y
Orbifloxacin (brand name Orbax) is a fluoroquinolone antibiotic which is approved for use in dogs,[1][2] marketed by Schering-Plough Animal Health.
See also
- Quinolone
References
- v
- t
- e
(inhibit bacterial
purine metabolism,
thereby inhibiting
DNA and RNA
synthesis)
DHFR inhibitor | |||||||||
---|---|---|---|---|---|---|---|---|---|
Sulfonamides (DHPS inhibitor) |
| ||||||||
Combinations |
| ||||||||
Other DHPS inhibitors |
(inhibit bacterial
topoisomerase
and/or DNA gyrase,
thereby inhibiting
DNA replication)
1st generation | |||||||||
---|---|---|---|---|---|---|---|---|---|
Fluoroquinolones |
| ||||||||
Newer non-fluorinated | |||||||||
Related (DG) |
inhibitors
Nitroimidazole derivatives |
---|
Rifamycins/ RNA polymerase | |
---|---|
Lipiarmycins |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e